scispace - formally typeset
Search or ask a question

Showing papers by "Clemens M. Wendtner published in 2019"

Journal Article•DOI•
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

[...]

Kirsten Fischer1, Othman Al-Sawaf1, Jasmin Bahlo1, Anna-Maria Fink1, Maneesh Tandon1, Mark Dixon1, Sandra Robrecht1, Simon Warburton1, Kathryn Humphrey1, Olga Samoylova1, Anna M. Liberati1, Javier Pinilla-Ibarz1, Stephen Opat1, Liliya Sivcheva1, Katell Le Du1, Laura M. Fogliatto1, Carsten Utoft Niemann1, Robert Weinkove1, Sue Robinson1, Thomas J. Kipps1, Sebastian Boettcher1, Eugen Tausch1, Rod A. Humerickhouse1, Barbara Eichhorst1, Clemens M. Wendtner1, Anton W. Langerak1, Karl Anton Kreuzer1, Matthias Ritgen1, Valentin Goede1, Stephan Stilgenbauer1, Mehrdad Mobasher1, Michael Hallek1 •
University of Cologne1
04 Jun 2019-The New England Journal of Medicine
TL;DR: Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutsumab and this benefit was also observed in patients with TP53 deletion, mutation, or both and in Patients with unmutated immunoglobulin heavy-chain genes.
Abstract: Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and ...

521 citations

Journal Article•DOI•
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.

[...]

Billy Michael Chelliah Jebaraj1, Eugen Tausch1, Dan A. Landau2, Jasmin Bahlo3, Sandra Robrecht3, Amaro Taylor-Weiner4, Johannes Bloehdorn1, Annika Scheffold1, Daniel Mertens1, Sebastian Böttcher5, Michael Kneba, Ulrich Jäger6, Thorsten Zenz7, Thorsten Zenz1, Michael Wenger8, Guenter Fingerle-Rowson8, Clemens M. Wendtner9, Anna-Maria Fink3, Catherine J. Wu4, Barbara Eichhorst3, Kirsten Fischer3, Michael Hallek3, Hartmut Döhner1, Stephan Stilgenbauer1 •
University of Ulm1, Cornell University2, University of Cologne3, Broad Institute4, University of Rostock5, Medical University of Vienna6, University of Zurich7, Hoffmann-La Roche8, Ludwig Maximilian University of Munich9
25 Mar 2019-Leukemia
TL;DR: Aside from identifying associations of short telomere length with adverse prognostic factors and survival, the study identified cases with 17p- and 11q- associated with TP53 and ATM loss, respectively, to have the shortest telomeres, even when these aberrations were present in small subclones.
Abstract: Telomere length in chronic lymphocytic leukemia (CLL) has been shown to be of prognostic importance, but the analyses have largely been executed on heterogeneous patient cohorts outside of clinical trials. In the present study, we performed a comprehensive analysis of telomere length associations in the well characterized CLL8 trial (n = 620) of the German CLL study group, with validation in a representative cohort of the CLL4 trial (n = 293). Absolute telomere length was analyzed using quantitative-PCR. Apart from identifying associations of short telomere length with adverse prognostic factors and survival, the study identified cases with 17p- and 11q- associated with TP53 and ATM loss, respectively, to have the shortest telomeres, even when these aberrations were present in small subclones. Thus, telomere shortening may precede acquisition of the high-risk aberrations, contributing to disease evolution. In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.

18 citations